RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 1, 2022

Study Completion Date

December 30, 2022

Conditions
Cholangiocarcinoma
Interventions
DEVICE

radiofrequency ablation

All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction

DRUG

Chemotherapy drug

Gemcitabine 1 000 mg/m2 intravenously on day 1,8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy

Trial Locations (1)

31006

Hangzhou First People's Hospital, Hangzhou

All Listed Sponsors
collaborator

Hangzhou Cancer Hospital

OTHER

collaborator

Changhai Hospital

OTHER

collaborator

Eastern Hepatobiliary Surgery Hospital

OTHER

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

collaborator

Xijing Hospital

OTHER

lead

First People's Hospital of Hangzhou

OTHER

NCT05028439 - RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma | Biotech Hunter | Biotech Hunter